I think we're ready to go. Great. Thanks, everyone. Thanks everyone for joining. This is our fireside chat with enGene. My name is David Dai. I'm a biotech analyst here at UBS. I cover mostly oncology, and it's a great pleasure to have Ron Cooper, Chief Executive Officer of enGene with us today. Ron, welcome.
David, real pleasure to be here. Thank you for the invitation.
Fantastic. enGene, very interesting story. Maybe, Ron, can just from a high-level perspective, just to help us understand a little more about enGene's story, especially you have a very interesting lead program called detalimogene. Tell us more about that.
Yeah. enGene is a unique company in that our company is focused on non-viral gene therapies. We have a unique platform called the DDX platform. From that platform, we have a product called detalimogene voraplasmid, which we're developing for non-muscle invasive bladder cancer. What's exciting about detalimogene is it's a well-advanced asset. We just put out some data very recently. We'll talk about that in a little bit. This is an asset that we plan to file the BLA by the end of this year, and we're going to expect an approval next year. What's pretty exciting is that we translated this unique technology, this non-viral gene therapy, into a medicine that we hope to have in the hands of urologists and patients with non-muscle invasive bladder cancer very soon.
Got it. Yeah, very interesting. So a non-viral approach towards HR NMIBC, non-muscle invasive bladder cancer. You know, the space is a little bit crowded, especially given the fact that there is adenovirus and others. Tell us a little bit more about this mechanism of this non-viral approach, and how is it different from the other approach that we are looking at here?
Well, it is totally unique, right? I think that is what makes it very, very special, because as you have indicated, David, there are chemo approaches, there are viral gene therapy approaches, and there are bacterial approaches. We are the only non-viral gene therapy. What makes detalimogene unique is it is actually a simple plasmid, not an LNP, with three genes in it, with our proprietary sugar that is pegylated. What is beautiful about that is that these are all readily available ingredients, and they are relatively easy to put together, so we have a very competitive cost of goods. Because it is non-viral, the handling, there is an aspect of cost of goods is handling, shipping, storage. This is a non-viral, so it is a lot easier to ship, handle, and store.
What is interesting about our approach is that combination of genes that we use, two RIG-I and one IL-12, that stimulates both the innate and adaptive immune system. So, when people are thinking about managing non-muscle invasive bladder cancer, which we believe is going to be a disease that gets sequenced much like multiple myeloma or others, detalimogene will be unique. It will be a different product within that sequence.
Got it. Just on that administration side, you said this is pretty convenient. Tell us a little bit more about, is this similar to BCG where you are doing transvesical delivery, and the handling, would you expect physician to use it kind of similar to what they are doing with BCG already?
BCG and better. So, yeah, it is intravesical. All these therapies are intravesical or administered. But, it's interesting, we recently had a patient in at the office talking about BCG therapy. We kind of take it for granted. But BCG therapy is an hour and a half dwell time. It's six weeks. It's intense. It has cumulative toxicity with it. The urine bleaching requirements require people two cups of bleach, right? So when you think about your lifestyle and things, if you're going to restaurants or if you're going to concerts or traveling, you're going to lug around all that bleach. When you think about detalimogene, first of all, is stored in a regular fridge or regular freezer, so same place where you put your ice cream or where you put your yogurt.
Yeah.
No special handling. Someone just reaches into the fridge, mixes with water. There's no pre-washes or anything like instill, and the patient can go from there. And then you see from our recent data that the tolerability profile is really quite impressive. We have the lowest treatment discontinuation rate and treatment interruption rate. So that's really a measure of the tolerability. So in fact, I would argue it's even easier than BCG to use.
Got it. So better administration, easier to use BCG, and off the shelf, I would imagine, you know, you just grab it from the fridge and administer it. So, very good. And the data, I think you just showed some interesting data last week, right? So help us walk us through that dataset. What did we learn from that?
Well, we learned that detalimogene is highly efficacious and well-tolerated on top of the great handling. So if we break it down for the efficacy parameters, all of our efficacy parameters improved since our last update, which is great. So when you think about it from an FDA perspective, the primary endpoint is complete response at any time. The detalimogene CR rate moved from 54% to 56%, which puts it right in the middle of the range of approved products. The next thing the FDA looks at is safety and tolerability, as I indicated to you. Even with increased exposures, the profile still holds really strong and with a very low rate of discontinuations, very low rate of treatment interruptions, really the lowest of all the products.
From a secondary endpoint perspective, the secondary endpoint is of those 56% of patients, what percentage are still in response 12 months and beyond? Most of the products, the approved products are in the 40s or 50s. Our Kaplan-Meier curve estimates that that will be 43%, and that jumped up from 25% to 43%. The other measures of durability that are looked at is median duration of response. Again, ours moved from 8.6 months to 10.1 months, and when you look at the confidence interval, the upper limit has not been reached yet, so there is still some time to get more. The last parameter, which is somewhat of a durability measure, although it is not in the label and it is not promotable, is the 12-month landmark complete response rate.
That jumped from 13% to 24%. If you put it all together, all efficacy parameters improved quite significantly, and even with increased exposures, tolerability held.
Got it. Very interesting, actually. A very compelling efficacy profile overall. As I said, the space is getting a little crowded, right? Especially we have now a few different approved products. We have most recently products from Johnson & Johnson, INLEXZO. We have already approved therapies like ADSTILADRIN from ImmunityBio and ANKTIVA, and also from KEYTRUDA. All these are approved products. How do you view the profile of efficacy profile compares to all these other approved therapies?
I think first of all, I do not like using the word competitive here, and I do not like using the term this is a small market. These are all complementary medicines. I am actually the biggest advocate for all of these products. One of the reasons that I am an advocate, I would start with a couple of numbers. If you look in the LEGEND study, 93% of the patients that were eligible that said, "We think you should have a radical cystectomy," said no. People do not want their organs removed. They do not want their bladders removed. Radical cystectomy, that is a big surgery. That has high mortality, and the morbidity associated with having an ostomy appliance, losing sexual function, it is not very good. There is a reason that people do not want to do that. So that is the first point.
The second point is, I've been spending a lot of time with patients of late, and when you meet a patient who decides they don't want their bladder removed, they don't want their bladder removed. They want anything that's available to them. What we see is a world going forward of where there will be multiple products being sequenced. That's already happening, but I would also say it's probably happening more in the academic and the academic-like centers. Those centers have the luxury of staff, they have the luxury of equipment to be able to use some of these newer products. Some of the first-generation products are just difficult to administer. There's a lot of pre-washes, there's special storage, you need BSL-2 hoods, you need to bleach afterwards. There's a lot that goes around that.
These products are predominantly being used in the academic and academic-like centers. When you think about where most of the patients are, 75% of the patients are in community-like settings. In these community settings, they have a shortage of staff, they have a shortage of equipment. The logistics are really important. Detalimogene represents what I would consider to be a next-generation type product that easily slides into the community practice where there are actually more patients. That combination of efficacy, of great tolerability, and ease of use, the hurdle rate to use that, I just believe makes it more attractive and actually will unlock the community setting. I just believe all of these new products are going to be sequenced because people want to keep their bladders.
Got it. One thing that you said is very interesting in sequencing. Where along the line of, let's say, first line, second line, third line, do you envision detalimogene would be used along that sequencing? Especially since, if, let's say, a drug will be used in front-line, where do you feel detalimogene will be used subsequent to that?
The nice thing about detalimogene, unlike any of the other approved products, it can be used if you're a urologist by yourself in Wisconsin, right, or at Sloan Kettering. It's one of the few products that has the ability to be used in all places. I think our feeling is that where most of the patients are in the academic centers, sorry, in the community centers, if you look at a couple other really important data points with detalimogene. We already talked a little bit about the convenience and ease of use, but in our recent data update, 91% of the patients respond in the first three months. Only 3% progress. If you make it to a year, if you get into the maintenance phase, 100% of those patients are durable.
So then, getting back to what I said before, if the hurdle rate for using this product is relatively easy, you can get efficacy really quickly, you will know if it works, and you do no harm, we believe in the community setting, this is a product that gets used very early. Very easy for the doctor to use, fits into the flow. Now, as we get closer to the academic centers, where we still think we are going to get a lot of usage there as well, the academics, what are they getting? They are getting patients that have already been exposed to gemcitabine, already been exposed to something else. They want to try something different, and that is where the fact that we are the only non-viral gene therapy becomes very attractive to them.
So we believe that detalimogene, for where the patients are being initiated earlier, but certainly for some of these patients that have been more experienced because it is a non-viral approach and the only one, it will be something different that the academics will be interested in as well.
Got it. And help us, maybe level set the market just a little bit more around how big do you envision this market is? Because we have seen reports of saying in BCG-unresponsive population, in high-risk NMIBC, you are looking at about 25,000 patients from an estimates standpoint. Just based on what you say, it seems like if you are going after sequencing, it could be even bigger than that. So help us understand a little bit more around where do you feel or do you see the market opportunity is for this one?
Well, I would agree with your estimates, but the estimates range from 25,000 to 40,000, right, and beyond, and as big as the whole total population around 125,000. And the reason nobody puts a finger on it is just because what you have described before. It is a dynamic market. It is a growing market. I would say the analogy would be, when REVLIMID was launched in multiple myeloma, that was roughly a $1 billion product, $1 billion market. Now you add over a dozen products in multiple myeloma. This is a $20 billion market size, and you see the sequencing through BiTEs and different types of products, right? I think we are at the dawn of something really great for patients with NMIBC and for the urologists, right? So, I think 20,000, 25,000 right now is a conservative estimate.
With these new products being approved, patients are going to require new medicines, and as I said, even the most potent product, the best ones, 50% of them need another medicine. The key thing here is patients don't progress to 20% over a 10-year time, to 20% progression, but they recur, and that's why you need those new medicines like detalimogene.
Got it. Yeah, that's really helpful here. Great. Since the data you just presented last week is a pivotal study, LEGEND study, the data actually could be supportive of FDA filing, and you said that you were actually looking to initiate a BLA filing end of this year, looking to complete it by early next year. What are some key next steps before you can actually start filing here?
Well, we just recently had a pre-BLA meeting with the FDA, and that went really well. On the basis of that, we've confirmed that we plan to initiate the filing by the end of this year. As you know, there are five modules to be filed. Two are administrative modules. Module three is the manufacturing module, and we've completed our FDA PPQ validation batches. The FDA gave us CDRP, so we've had a lot of dialogue on manufacturing, so it's not a throw it over the fence situation. We feel really good about that module. What people forget is that's usually the biggest module. That's probably five times the size of the clinical module. Module four is the preclinical module, which we've had done for a while, and then module five is the clinical module.
Here, as we shared with our data, most of our patients are through. We have nine more patients to go, so we'll find a mechanism to put those in a little bit later on. We're in great shape. We anticipate initiating the filing this year, and we expect an approval in 2027.
Got it. You mentioned that the FDA meeting aligned with the FDA in terms of patient numbers as well, right? The most recent update, you actually took out five patients from that addressable population. Tell me a little bit more about why. What's the reason behind those five patients, and why did the FDA allow you to eliminate or exclude those five patients accordingly?
Yeah, that's pretty standard, right? As you finish enrollment of your pivotal program, you have a discussion with the FDA on the statistical analysis plan. It's pretty important in a pre-BLA, and we need to align on the efficacy evaluable population, because when you're completing module five, you need to know what patients are going in there. We agreed with the FDA on the major points of the statistical analysis plan. That resulted in us going from 125 to 120 patients. These were five patients that didn't really fit the criteria that they put forward on. They either didn't have a follow-up measurement, they either didn't have adequate BCG, or they didn't have carcinoma in situ in the right timeframe. That homogenizes the patient population. This, as you've seen with other products, it's pretty common.
If you see what they publish and what gets into the label, there usually is a change in five out of 125, which is one of the larger NMIBC databases, is actually quite small.
Got it. As part of this FDA alignment, did FDA agree on what we consider approval from any type of CR, durability standpoint? What did FDA say in terms of, what's the hurdle going to be for these kind of parameters on the efficacy side?
Yeah, I hear that word hurdle a lot. I think that's a Wall Street name. The FDA doesn't have hurdles. The FDA, in general, looks at every product on the basis of risk and benefits, right? In our case, we think about risk, as I said to you before, lowest treatment interruption, lowest discontinuations. If I put detalimogene and put it on your hands, nothing's going to happen. I would never do that, but nothing is going to happen. So, the non-viral approach from a risk perspective is low. Then you look at the primary endpoint. The primary endpoint, that's what they weight at 56% CR rate anytime is in the range of other products. Then, as I shared with you, that cluster of durability metrics, our product lasts a reasonable amount of time.
I don't think they would be allowing us to initiate the filing, right? Normally, the FDA, if they tell you to file something, they intend to approve that as well. So, I would say that we're in pretty good shape, and we feel very good about the package. We feel very good about our FDA dialogue. We'll get the filing in this year, and then we look forward to an approval in 2027.
Great. So, end of this year, initiating the filing, completing by early next year, and potential approval next year. So, that's actually going to be quite a bit of catalyst going forward. Have you done any work in terms of the market, assessing the commercial opportunity? What's kind of the commercial work that you've done so far in terms of trying to establish the market and engaging with the community of physicians so far? Tell us a little bit more around the commercial side, because launching is soon.
Yeah. Well, we've been very active. We've been delighted that our Chief Global Commercialization Officer, Amy Pott, has been with us with quite some time. We have a terrific head of medical affairs as well. So, we've had medical affairs folks on the ground already. We've been doing extensive market research to really understand the customer bases and where the customers are. If you look at the launch pedigree within our organization, Amy has launched multiple products through her time at Shire, through Astellas. I've launched dozens of products all over the world. My previous company, we had a product approved, launched in the U.S. and in Europe. So, I think we feel pretty confident about our launch plans. We're on track in our commercialization efforts, our early efforts.
Now that we've had the updated data, which shows improvements in all efficacy parameters and holding from a community standpoint, and we will be initiating the filing, it's time to gear up a lot more. So, the intensity of what we're doing is going to pick up, as you would expect, as we get closer to launch.
Got it. Is there any early feedback from physicians so far, especially in the community setting? Did you bring this updated data over to the community physicians, and how do they view that?
Well, it's interesting you say that, because we put out some interim data earlier in the year that the market did not react very well to. Paradoxically, that very week, we went to the American Urological Association meeting, and the doctors were like, "Oh, this looks great," or, "This is right in range of what we expect. This is a non-viral approach." So, even in the data that we had previously, where we were within range from a primary endpoint, but our durability data was immature. We only had five and a half months of follow-up on that. Now that the data is matured, we would expect the commentary to be even better. So, we did have a small advisory board earlier, before that data came out, and it was like two thumbs up from that.
Now that we just put the data out next week, our medical affairs teams are engaging and gaining feedback, and there's some upcoming meetings as well. So, I think in general, what we're hearing from urologists is they're just excited to have actual medicines that can help these patients, and the fact that this is a non-viral gene therapy that they can actually use anywhere, in a small community practice, in an academic setting, they're getting pretty excited about things. So, the feedback's been terrific.
Fantastic. That is great to hear. Great work. Just to kind of for the next seven minutes or so, love to dive into the other aspect of your development, which is you are actually running this surfactant cohort with the detalimogene, basically adding a surfactant rinse, right? The idea here is, with the surfactant rinse, you are able to have potentially better penetration of IL-12 expression in the bladder wall. Tell us a little bit more about that. What gives you confidence that this increased expression of IL-12 would give rise to better efficacy, CR, anytime CR, and durability standpoint?
Well, I think it first starts off with what are we tracking with detalimogene right now? We are tracking what we would consider to be potentially best-in-class tolerability, best-in-class safety and handling, best-in-class cost of goods, and in-class efficacy, right? But we are a company that is trying to do things that are better for patients, so we have always had life cycle management plans in our place. How do we make detalimogene even more convenient and even more efficacious? We have been looking at surfactant bladder rinses for quite some time, right? If you think about it, we think that we can actually boost efficacy, but also improve convenience by reducing the dwell time. What is the basis of belief for that?
First of all, if you look at the viral gene therapies, the one approved and the one in development, you look at their preclinical models, without a surfactant bladder rinse, you get very little or no transfection at all. You add a surfactant bladder rinse, you improve transfection. What is great about detalimogene with the proprietary DDX formulation that we have, that without a bladder rinse, a surfactant bladder rinse, we get transfection. You can see that. But if you add a surfactant bladder rinse, we have selected polidocanol, which is an approved product with a lot of data behind it, you get both better depth and breadth of transfection. That is really interesting. If you look at both our murine models and in validating NHPs, that is up to 10 x increase in IL-12 expression. So that is really interesting for us.
What we have done is we started another cohort of patients, very similar to the pivotal cohort, the exact same inclusion/exclusion criteria. What we are doing is administering a very short bladder rinse, five minutes. So you put it in, take it out, same catheter, then you put detalimogene in. But then we are cutting the dwell time by 50% as well. That should give what we hope to provide is a double bonus for patients, because we have to remember, these are patients who have gone through a lot. These are beaten-up bladders, they are already incontinent. Holding it in is difficult. So reduction of 50%, with the trade-off with just a little extra time with the bladder rinse should net savings of 25 minutes. What we are pleased is we are up and going with this cohort of patients. We have cleared the safety run-in, which is great.
It's the first time that we've used polidocanol in the bladder. Now we're enrolling that, and we're looking forward to providing an update mid-next year with that cohort of patients.
Got it. For that data update mid-next year, could you just help us a little more around expectation around the number of patients we should be looking for? Is there any internal bar? Are we looking for, let's say, 10x, 15 x better than what we're already seeing with detalimogene? What do we think in terms of efficacy?
Yeah. I think first of all, what we're looking for is somewhere around 20-ish patients mid-next year, six months data. I think the other thing that we should be able to see is, from a PD perspective, we have detalimogene IL-12, then we'll have IL-12 with these patients that have the surfactant. So we hope to show a difference in that. It won't be the same as in the preclinical models where it's up to 10 x increase, because we don't want to take people's bladders out and chop them up and look at them. But we'd like to see from PD perspective an increase in IL-12. I think the first win for us, so we'd like to see that from PD perspective.
The second thing is if we can have the exact same efficacy and we go down to half the time of dwell time, that would be a win on top of that. Any extra efficacy we get or extra durability, that would be a bonus as well. So I think there are multiple wins for us with these surfactant bladder rinse.
Got it. The expectation is to have another BLA after, because we would imagine the detalimogene will be approved next year, right? The data for cohort two, sorry, the surfactant cohort will probably come a little bit later or around the same time. Is the expectation to add this as top of label without a study, or are you looking to submit another BLA for the surfactant cohort?
Yeah. Right now, our current plans is that the surfactant cohort will be an sBLA, so it will be a supplementary. I think for us is we're very focused. We're very focused right now in getting this BLA in, very focused in on getting the approval, very focused in on building up our commercial capabilities so we can launch this thing successfully. On the back of that strong base to put a supplementary in, I think, is the strategy that we believe is the most prudent.
Got it. Great. For next 6 to 12 months, maybe just help us understand a little more around what kind of catalysts we should be looking for here. What would be key focus or deliverables you're looking to do?
Yeah. I think this is a catalyst-rich period. I believe that it's only going to get better here. As we said, even in May, we just need time, right? By the end of this year, we expect to initiate the filing. Sometime early next year, the FDA will tell us they've accepted the filing. Mid-2027, we will have the detalimogene plus surfactant cohort, and we expect by the end of next year to have an approval for detalimogene. As I said, this is a catalyst-rich timeframe, and as time goes on, we're going to know more that de-risks what we're doing even more so. To me, it's a good time now, but it's going to get better over time.
Awesome. Great, Ron. This is really good, and I am looking forward to a data-rich 2027 with multiple catalysts, including approval and also potentially update from the surfactant cohort.
David, thanks again. We are pretty excited at enGene. The company has existed for a number of years, so to get detalimogene approved and to patients with NMIBC as the only non-viral gene therapy, things could be very special here for us.
Great. Thank you so much, Ron. Really appreciate it.
Thank you.
All right. Take care.